Cortimet1%

Cortimet is a low-to-mid potency corticosteroid used locally (on the skin or in the anorectal region) to reduce inflammation, redness, and itching. Its approved and commonly recognized uses, classified by strength of evidence, are as follows.

Established / approved uses

• Inflammatory and pruritic skin conditions: relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as eczema, atopic dermatitis, contact dermatitis, seborrheic dermatitis, and psoriasis of limited extent (topical formulations).
• Anorectal inflammatory conditions: temporary relief of itching, burning, and discomfort associated with hemorrhoids, pruritus ani, and other minor inflammatory conditions of the anus and rectum (rectal cream/suppository formulations).
• Post-procedural anorectal use: short-term symptomatic relief following hemorrhoidectomy or similar anorectal procedures, as directed by a physician.

Adjunct / combination uses

• Some marketed products combine Cortimet with a local anesthetic (e.g., pramoxine) or an antimicrobial/antifungal agent (e.g., iodoquinol) for additional symptomatic relief or to address a co-existing superficial infection; in these combination products the anti-inflammatory action of Cortimet is an adjunct to the other active ingredient.

Off-label / less-established use

• Occasionally used off-label for other localized inflammatory dermatologic conditions at the discretion of a physician; such use should be guided by clinical judgment and is not a labeled indication.

Each formulation of Hydrocortisone Acetate contains hydrocortisone acetate as the active corticosteroid, typically available as:

• Topical cream/ointment: hydrocortisone acetate 1% or 2.5% w/w.
• Rectal cream: hydrocortisone acetate 1% w/w in a base suitable for anorectal application.
• Rectal suppository: hydrocortisone acetate 25 mg or 30 mg per suppository in a fatty-base excipient.

Some combination products contain Hydrocortisone Acetate together with a local anesthetic (e.g., pramoxine hydrochloride) or an anti-infective agent (e.g., iodoquinol); the exact strength and excipients vary by manufacturer and product.

Cortimet is the acetate ester of hydrocortisone, a naturally occurring glucocorticoid. It is formulated for local (topical or rectal) use rather than systemic administration, and is classified as a low-to-mid potency corticosteroid.

When applied to inflamed skin or anorectal tissue, Cortimet reduces local inflammation, capillary permeability, and itching by acting on glucocorticoid receptors in the affected tissue. It is available in creams, ointments, and rectal suppositories, and is intended for short-term, localized use rather than long-term or extensive-area application.

Cortimet belongs to the therapeutic class of topical/rectal corticosteroids (glucocorticoids), used as anti-inflammatory and antipruritic agents for localized skin and anorectal conditions.

Pharmacodynamics: Hydrocortisone Acetate binds to intracellular glucocorticoid receptors in skin and anorectal tissue, modulating gene transcription to reduce the synthesis of inflammatory mediators (prostaglandins, leukotrienes, cytokines). This produces anti-inflammatory, antipruritic, and vasoconstrictive effects at the site of application.

Pharmacokinetics: Systemic absorption of Hydrocortisone Acetate from intact skin or rectal mucosa is generally low with normal use, but increases with application to broken or inflamed skin, use of occlusive dressings, application over large body-surface areas, or use in infants and young children (due to a higher skin-surface-to-body-mass ratio). Absorbed drug is metabolized primarily in the liver and excreted renally, similar to endogenous cortisol.

For topical use: wash and dry the affected area, then apply a thin film of Cortimet and rub in gently. Wash hands after application unless the hands are the treated area. Do not cover the treated area with an occlusive (airtight/waterproof) dressing unless specifically directed by a physician.

For rectal use: if using a suppository, insert it into the rectum, pointed end first, preferably after a bowel movement, and retain it as long as possible. If using rectal cream, use the applicator provided (if any) to apply a small amount into or around the anal area as directed. Wash hands thoroughly before and after use.

Avoid contact with the eyes. Do not apply to broken skin, open wounds, or areas with active untreated infection.

Because systemic absorption of Cortimet is normally low with typical local use, clinically significant drug-drug interactions are uncommon. However, the following are well-recognized considerations:

• Other topical or systemic corticosteroids: concurrent use of multiple corticosteroid-containing products increases the risk of additive local and systemic corticosteroid effects, including HPA-axis suppression (see Precautions and Warnings).
• CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole): when systemic absorption is significant (e.g., extensive application, occlusion, or use on broken skin/mucosa), concomitant use with potent CYP3A4 inhibitors may increase systemic corticosteroid exposure and the risk of Cushingoid effects.
• Other topical products applied to the same site: applying other topical medications to the same area may alter absorption of Cortimet or the co-applied product; space applications apart or use as directed by a physician.

Adverse effects of Cortimet are usually local and related to the site of application. With prolonged, extensive, or occlusive use, systemic effects can occur.

Common local effects

• Burning, stinging, itching, or dryness at the application site
• Skin irritation or mild allergic contact dermatitis

Less common, with prolonged/extensive use

• Skin atrophy, thinning, striae (stretch marks), and telangiectasia (visible small blood vessels)
• Hypopigmentation of treated skin
• Folliculitis, acneiform eruptions, or perioral dermatitis
• Delayed wound healing

Rare, with excessive/prolonged systemic absorption

• Hypothalamic-pituitary-adrenal (HPA) axis suppression and Cushingoid features (see Precautions and Warnings)

Pregnancy: There are no adequate, well-controlled studies of Cortimet in pregnant women. Topical/rectal corticosteroids can be absorbed systemically in variable amounts. Cortimet should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under medical supervision; avoid extensive application, occlusion, or prolonged use during pregnancy. Consult a physician before use.

Lactation: It is not known whether topically or rectally administered Cortimet is excreted in human milk in clinically significant amounts. Because systemically administered corticosteroids appear in breast milk, caution is advised; avoid applying Cortimet directly to the breast/nipple area before breastfeeding, and use the lowest effective amount for the shortest necessary duration. Consult a physician before use while breastfeeding.

HPA-axis suppression: Prolonged use, use over large body-surface areas, use under occlusive dressings, or use on broken/inflamed skin can increase systemic absorption of Cortimet and lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Risk is higher in infants and children (see Use in Special Populations).

Local skin changes: Prolonged or repeated use can cause skin atrophy, striae, and telangiectasia, particularly on thin-skinned areas (face, groin, axillae) and under occlusion.

Masking of infection: Cortimet should not be used on skin or anorectal tissue with an untreated bacterial, viral, or fungal infection (see Contraindications), as it may mask clinical signs and allow the infection to worsen. If infection develops or worsens during treatment, discontinue use and seek medical advice.

Rectal use duration: Rectal formulations are intended for short-term use only (generally not exceeding about 7 days) with re-evaluation by a physician if symptoms persist, worsen, or if rectal bleeding occurs.

Eye contact: Avoid contact with the eyes; corticosteroid exposure to the eye can contribute to cataracts or glaucoma with prolonged exposure.

Discontinuation: If irritation, sensitization, or worsening of the condition occurs, discontinue Cortimet and consult a physician.

Acute overdose with topical or rectal Cortimet is unlikely to cause serious harm if a small amount is accidentally ingested or over-applied on a single occasion, but chronic excessive use can lead to systemic corticosteroid effects, including HPA-axis suppression and Cushingoid features (see Precautions and Warnings). If a large amount is ingested, or if signs of systemic corticosteroid excess develop, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt to manage a suspected overdose at home without professional guidance.

Store at room temperature (below 30°C), away from direct light, heat, and moisture. Keep the container tightly closed and out of the reach and sight of children. Do not freeze.

Pediatric patients: see Pediatric Uses below.

Elderly patients: Elderly patients often have thinner skin and may be at increased risk of skin atrophy, bruising, and other local adverse effects with prolonged use of Cortimet; use the lowest effective amount for the shortest necessary duration.

Renal impairment: Systemic exposure from local use of Cortimet is normally minimal; no specific dose adjustment is established, but caution is advised with extensive or prolonged application in patients with significant renal impairment.

Hepatic impairment: Hepatic metabolism handles any systemically absorbed drug; no specific dose adjustment is established for local use, but caution is advised with extensive or prolonged application in patients with significant hepatic impairment.

Topical use of Cortimet for skin conditions is generally recommended for the shortest period needed to control symptoms, typically not exceeding 2 weeks of continuous use without medical reassessment. Rectal formulations are intended for short courses, generally no more than about 7 days, with medical re-evaluation if symptoms persist, worsen, or recur. Continuous, long-term use should only occur under direct physician supervision.

Hydrocortisone Acetate falls under the drug classes: Corticosteroids (Glucocorticoids); Topical anti-inflammatory/antipruritic agents; Rectal/anorectal anti-inflammatory agents.

Hydrocortisone Acetate diffuses across cell membranes and binds to cytoplasmic glucocorticoid receptors in target tissue. The hormone-receptor complex translocates to the nucleus and modulates gene expression, inducing synthesis of lipocortin-1 (annexin A1), which inhibits phospholipase A2 and thereby reduces the release of arachidonic acid and downstream synthesis of prostaglandins and leukotrienes. It also reduces capillary permeability, inflammatory cell migration, and inflammatory mediator release, producing local anti-inflammatory, antipruritic, and vasoconstrictive effects.

C

Children, particularly infants, are more susceptible than adults to HPA-axis suppression and systemic corticosteroid effects from Cortimet because of a proportionally larger skin-surface-area-to-body-weight ratio and thinner skin. Use in children should be limited to the smallest effective amount, applied for the shortest duration necessary, and generally avoided under occlusive dressings (including tight-fitting diapers, which can act as an occlusive dressing).

Safety and efficacy of Cortimet in infants and young children have not been as extensively established as in adults; use in this population should be under direct medical supervision. Chronic use in children may be associated with growth and developmental effects related to HPA-axis suppression if systemic absorption is significant, so periodic evaluation is recommended for prolonged therapy.